Used in pharmaceutical research as a key intermediate in the synthesis of cereblon modulators, particularly in the development of targeted protein degradation therapies such as PROTACs. Its structure enables selective binding to E3 ubiquitin ligase, facilitating the breakdown of disease-causing proteins. Investigated for potential applications in oncology, especially in hematological malignancies like multiple myeloma and leukemia. Also explored for anti-inflammatory and immunomodulatory effects in preclinical studies.